Fibrocell Science Inc

Fibrocell Science — Investor Presentation (January 2017)

19 slides from Fibrocell Science's investor presentation, Jan 9, 2017

  1. Slide 1: Corporate Presentation January 9, 2017

    Corporate Presentation January 9, 2017

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this pu

  3. Slide 3: Fibrocell at a Glance

    Proprietary autologous fibroblast cell capabilities + Ex vivo genetic modification of patients’ own fibroblast cells FCX-007 Recessive Dystrophic Epidermolysis Bullosa (RDEB) FCX-013 Linear Scleroderma Arthritis and related conditions 3 Fibrocell at a Glance Personalized medical breakthroughs for di

  4. Slide 4: Our Autologous Fibroblast Gene Therapy Platform

    Autologous fibroblasts harvested from patients • Readily sourced, as fibroblasts are the most common cell type in skin and connective tissue • Reduced rejection and immunogenicity concerns because the donor is the patient • Established manufacturing process and regulatory pathway for autologous fibr

  5. Slide 5: Personalized Biologics Approach

    Personalized Biologics Approach 5

  6. Slide 6: Development Pipeline

    Development Pipeline 6 Personalized Biologic Condition Research Pre-Clinical Development Human Clinical Trials FCX-007 Recessive Dystrophic Epidermolysis Bullosa (RDEB) FCX-013 Linear Scleroderma Research Program Arthritis Human data expected 3Q17 IND filing expected 4Q17

  7. Slide 7: FCX-007 Providing Hope for RDEB Patients

    FCX-007 Providing Hope for RDEB Patients 7 RDEB patients do not produce type VII collagen (COL7) due to mutation in COL7A1 gene • Main component of anchoring fibrils that connect skin layers FCX-007 is an autologous human dermal fibroblast transduced with a lentiviral (LV) vector encoded for COL7A1

  8. Slide 8: Recessive Dystrophic Epidermolysis Bullosa

    Recessive Dystrophic Epidermolysis Bullosa 8 Disease Current Treatments Epidemiology • Cause: A mutation in the COL7A1 gene that encodes for COL7 • Devastating, progressive, painful blistering disease that often leads to death • Diagnosed at infancy • High mortality rate – 76% of RDEB suffers do not

  9. Slide 9: Functional COL7 Expression Confirmation

    Functional COL7 Expression Confirmation 9 Culture supernatant evaluated for in vitro COL7 expression • ELISA assay indicates virus dose-dependent protein expression • Trimeric form of COL7 produced by RDEB patient fibroblasts transduced with LV-COL7 •Must be trimeric to be functional Reference: Bruc

  10. Slide 10: Detection of COL7 Expression by Immunofluorescence

    10 Detection of COL7 Expression by Immunofluorescence (Magnification 20x) • In vitro COL7 expression noted from FCX-007 replicates (red) • FCX-007 expresses higher levels of COL7 than normal human dermal fibroblasts (NHDF) as depicted by a brighter signal • No expression of COL7 in RDEB-positive fib

  11. Slide 11: Long-lasting COL7 Persistence Expected

    11 Long-lasting COL7 Persistence Expected Fibroblast Cells • Autologous cells minimize rejection risk • Direct administration of FCX-007 to the upper dermis ensures COL7 is expressed in the basement membrane zone where anchoring fibrils are formed • Lower turnover rate than other skin cells such as

  12. Slide 12: FCX-007 Phase I/II Clinical Trial Design

    FCX-007 Phase I/II Clinical Trial Design 12 Title A Phase I/II Trial of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Objectives Primary 1) To evaluate the safety of FCX-007 Secondary 1) To evaluate mechanism of action of FCX

  13. Slide 13: FCX-013 Development Progressing

    FCX-013 Development Progressing 13 • Product profile  Autologous fibroblasts genetically modified using lentivirus and encoded for a protein responsible for breaking down excess collagen  Target protein known to breakdown collagens  Incorporates Intrexon’s RheoSwitch Therapeutic System® (RTS®) to

  14. Slide 14: FCX-013 employs Intrexon's RheoSwitch Therapeutic System

    • FCX-013 employs Intrexon’s RheoSwitch Therapeutic System® (RTS®)  The RTS® biologic switch is activated by an orally- administered activator ligand (AL) that provides the ability to control level and timing of protein expression • Enhances the safety profile of FCX-013 by providing control over t

  15. Slide 15: Lead Indication: Linear Scleroderma

    Lead Indication: Linear Scleroderma 15 Disease Epidemiology • Excess production of collagen characterized by skin fibrosis and linear scars • The linear areas of skin thickening may extend to underlying tissue and muscle in children which may impair growth in affected legs and arms or forehead • Les

  16. Slide 16: FCX-013 Proof-of-Concept Study

    FCX-013 Proof-of-Concept Study 16 • Study Design  Bleomycin treated SCID mouse model  N=30 mice over test and control groups  Assessed histologically for reduction of dermal thickness and sub-dermal muscle in the presence of FCX-013 and oral ligand • Result  Bleomycin treatment resulted in skin

  17. Slide 17: Research Program for Arthritis

    Research Program for Arthritis 17 • Deliver therapeutic protein locally to the joint providing sustained efficacy while avoiding key side effects typically associated with systemic therapy • Combines Fibrocell’s autologous fibroblast technology with Intrexon’s cellular engineering to develop localiz

  18. Slide 18: Milestones and Financials

    Milestones and Financials 18 Milestones Anticipated Timing FCX-007 1st Adult Subject Dosed 1Q17 (FCX-007 cells harvested, pre-dose testing in process) FCX-007 Phase I/II Trial First human clinical data 3Q17 FCX-013 IND Submission 4Q17 Financials • Cash = $21.3 million at 30 September 2016 (unaudited

  19. Slide 19: References

    References 1 Fritsch A., et. al. A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanism of disease and response to fibroblast therapy. J Clin Invest.2008; 118:1669–1679. 2 Fine, J. et. al. (ed.). Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances and the

Fibrocell Science — Investor Presentation (January 2017) on 6ix